Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Schema
  9. External Links
  10. Analytics And Tracking
  11. Libraries
  12. CDN Services

We are analyzing https://link.springer.com/article/10.1186/s12885-020-06818-0.

Title:
All-trans retinoic acid reduces cancer stem cell-like cell-mediated resistance to gefitinib in NSCLC adenocarcinoma cells | BMC Cancer
Description:
Background The enrichment of cancer stem cell-like cells (CSCs) has been considered to be responsible for tumor progression after an initial response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) in patients with non-small cell lung adenocarcinoma (NSCLC/ADC). CSCs with ALDH1A1bright /CD44high expression contribute to the TKIs resistance in NSCLC/ADC cells. All-trans retinoic acid (ATRA) has been shown to be a potential targeted therapy against CSCs due to its ability to inhibit ALDH1A1 activity. We therefore investigated whether ATRA could circumvent the resistance to improve the response to gefitinib in NSCLC/ADC cells. Methods Treatment of NSCLC/ADC A549 and H1650 cells with gefitinib enriched the gefitinib surviving cells (GSCs). The expression of ALDH1A1 and CD44 and the IC50 values for gefitinib were determined by flow cytometry (FCM) and crystal violet assay in GSCs and ATRA-treated GSCs, respectively. Using DEAB as the positive control, direct inhibitory effect of ATRA on ALDH1A1 activity was determined by ALDEFLUOR assay, Results GSCs showed higher expression of ALDH1A1 and CD44 and IC50 values for gefitinib than their respective parental cells, suggesting that gefitinib can lead to propagation of CSC-enriched gefitinib-resistant cells. Treatment with ATRA was found to significantly reduce the increased expression of ALDH1A1 and CD44 and the IC50 values for gefitinib in A549GSC and H1650GSC cells, and ATRA could directly inhibit active ALDH1A1 as compared to DEAB. Conclusion Our findings suggest that combination treatment with ATRA prevents gefitinib-induced enrichment of ALDH1A1bright/CD44high CSCs and enhances gefitinib-induced growth inhibition of NSCLC/ADC cells.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {šŸ“š}

  • Science
  • Education
  • Health & Fitness

Content Management System {šŸ“}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {šŸ“ˆ}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 8,177,289 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {šŸ’ø}

The income method remains a mystery to us.

The purpose of some websites isn't monetary gain; they're meant to inform, educate, or foster collaboration. Everyone has unique reasons for building websites. This could be an example. Link.springer.com could have a money-making trick up its sleeve, but it's undetectable for now.

Keywords {šŸ”}

cancer, cells, cell, pubmed, article, gefitinib, lung, atra, resistance, cas, google, scholar, aldha, expression, acid, retinoic, nsclc, egfr, cscs, growth, stem, treatment, agsc, data, receptor, hgsc, egfrtkis, inhibition, rarβ, activity, nonsmall, central, mutation, factor, nsclcadc, fig, apoptosis, tumor, response, patients, celllike, kinase, control, acquired, alltrans, inhibitors, shown, therapy, showed, compared,

Topics {āœ’ļø}

n-[3-chloro-4-fluorophenyl]-7-methoxy-6-[3-morpholinopropoxy]quinazolin-4- amine egfr-tki-resistant aldh1a1bright/cd44high csc gadd153-ccaat-enhancing binding protein-β net/cancer-types/lung-cancer ccaat/enhancer-binding protein beta jun n-terminal kinase csc-enriched gefitinib-resistant cells csc cell-mediated resistance gsc-enriched gefitinib-resistant cells egfr-mutant lung cancers ccaat-enhancing binding protein drug-resistant cancer cells article download pdf small-cell lung cancer reduce csc-mediated resistance aldh1a1bright/cd44high cell population egfr-tkis exposure influences tyrosine kinase inhibitors therapeutic anti-csc trans retinoic acid trans-retinoic acid receptor class-selective retinoids retinoic acid receptor potential therapeutic targets egfr-tkis maintenance therapy tris/acetate/edta pcr cell-mediated resistance aldh1a1-negative cell population cancer therapies egfr/wnt signaling pathways retinoic acid signaling lung cancer stem aldehyde dehydrogenase inhibitors cancer stem cell cancer stem cell full access high atra levels quantitative fluorescence pcr gata-binding factor 6 retinoic acid receptors cell death dis cancer drug resistance short-term gefitinib treatment promising therapeutic strategy aldh1a1bright/cd44high cscs linked tumor stem cell cancer stemness induced cancer stem cells aldh/nrf2 signaling privacy choices/manage cookies

Schema {šŸ—ŗļø}

WebPage:
      mainEntity:
         headline:All-trans retinoic acid reduces cancer stem cell-like cell-mediated resistance to gefitinib in NSCLC adenocarcinoma cells
         description:The enrichment of cancer stem cell-like cells (CSCs) has been considered to be responsible for tumor progression after an initial response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) in patients with non-small cell lung adenocarcinoma (NSCLC/ADC). CSCs with ALDH1A1bright /CD44high expression contribute to the TKIs resistance in NSCLC/ADC cells. All-trans retinoic acid (ATRA) has been shown to be a potential targeted therapy against CSCs due to its ability to inhibit ALDH1A1 activity. We therefore investigated whether ATRA could circumvent the resistance to improve the response to gefitinib in NSCLC/ADC cells. Treatment of NSCLC/ADC A549 and H1650 cells with gefitinib enriched the gefitinib surviving cells (GSCs). The expression of ALDH1A1 and CD44 and the IC50 values for gefitinib were determined by flow cytometry (FCM) and crystal violet assay in GSCs and ATRA-treated GSCs, respectively. Using DEAB as the positive control, direct inhibitory effect of ATRA on ALDH1A1 activity was determined by ALDEFLUOR assay, GSCs showed higher expression of ALDH1A1 and CD44 and IC50 values for gefitinib than their respective parental cells, suggesting that gefitinib can lead to propagation of CSC-enriched gefitinib-resistant cells. Treatment with ATRA was found to significantly reduce the increased expression of ALDH1A1 and CD44 and the IC50 values for gefitinib in A549GSC and H1650GSC cells, and ATRA could directly inhibit active ALDH1A1 as compared to DEAB. Our findings suggest that combination treatment with ATRA prevents gefitinib-induced enrichment of ALDH1A1bright/CD44high CSCs and enhances gefitinib-induced growth inhibition of NSCLC/ADC cells.
         datePublished:2020-04-15T00:00:00Z
         dateModified:2020-04-15T00:00:00Z
         pageStart:1
         pageEnd:9
         license:http://creativecommons.org/publicdomain/zero/1.0/
         sameAs:https://doi.org/10.1186/s12885-020-06818-0
         keywords:
            All-trans retinoic acid
            ALDH1A1
            CD44
            EGFR tyrosine kinase inhibitors
            Non-small cell lung adenocarcinoma
            Cancer Research
            Oncology
            Surgical Oncology
            Health Promotion and Disease Prevention
            Biomedicine
            general
            Medicine/Public Health
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12885-020-06818-0/MediaObjects/12885_2020_6818_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12885-020-06818-0/MediaObjects/12885_2020_6818_Fig2_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12885-020-06818-0/MediaObjects/12885_2020_6818_Fig3_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12885-020-06818-0/MediaObjects/12885_2020_6818_Fig4_HTML.png
         isPartOf:
            name:BMC Cancer
            issn:
               1471-2407
            volumeNumber:20
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Wenxiu Yao
               affiliation:
                     name:Medical School of University of Electronic Science and Technology of China
                     address:
                        name:Department of Medical oncology, Sichuan Cancer Hospital, Medical School of University of Electronic Science and Technology of China, Chengdu, People’s Republic of China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Liyang Wang
               affiliation:
                     name:Medical School of University of Electronic Science and Technology of China
                     address:
                        name:Department of Medical oncology, Sichuan Cancer Hospital, Medical School of University of Electronic Science and Technology of China, Chengdu, People’s Republic of China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Huan Huang
               affiliation:
                     name:Wuming Hospital Affiliated to Guangxi Medical University
                     address:
                        name:Department of Medical oncology, Wuming Hospital Affiliated to Guangxi Medical University, Nanning, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Xin Li
               affiliation:
                     name:Medical School of University of Electronic Science and Technology of China
                     address:
                        name:Department of Medical oncology, Sichuan Cancer Hospital, Medical School of University of Electronic Science and Technology of China, Chengdu, People’s Republic of China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Pinjia Wang
               affiliation:
                     name:Medical School of University of Electronic Science and Technology of China
                     address:
                        name:Department of Medical oncology, Sichuan Cancer Hospital, Medical School of University of Electronic Science and Technology of China, Chengdu, People’s Republic of China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Kun Mi
               affiliation:
                     name:Sichuan Cancer Insititute
                     address:
                        name:Department of Biochemistry & Molecular Biology, Sichuan Cancer Insititute, Chengdu, People’s Republic of China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jia Cheng
               affiliation:
                     name:Sichuan Cancer Insititute
                     address:
                        name:Department of Biochemistry & Molecular Biology, Sichuan Cancer Insititute, Chengdu, People’s Republic of China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Huifen Liu
               affiliation:
                     name:Sichuan Cancer Insititute
                     address:
                        name:Department of Biochemistry & Molecular Biology, Sichuan Cancer Insititute, Chengdu, People’s Republic of China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Cuirong Gu
               affiliation:
                     name:Sichuan Cancer Insititute
                     address:
                        name:Department of Biochemistry & Molecular Biology, Sichuan Cancer Insititute, Chengdu, People’s Republic of China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Lingxiao Huang
               affiliation:
                     name:Sichuan Cancer Insititute
                     address:
                        name:Department of Biochemistry & Molecular Biology, Sichuan Cancer Insititute, Chengdu, People’s Republic of China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jianming Huang
               affiliation:
                     name:Sichuan Cancer Insititute
                     address:
                        name:Department of Biochemistry & Molecular Biology, Sichuan Cancer Insititute, Chengdu, People’s Republic of China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:All-trans retinoic acid reduces cancer stem cell-like cell-mediated resistance to gefitinib in NSCLC adenocarcinoma cells
      description:The enrichment of cancer stem cell-like cells (CSCs) has been considered to be responsible for tumor progression after an initial response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) in patients with non-small cell lung adenocarcinoma (NSCLC/ADC). CSCs with ALDH1A1bright /CD44high expression contribute to the TKIs resistance in NSCLC/ADC cells. All-trans retinoic acid (ATRA) has been shown to be a potential targeted therapy against CSCs due to its ability to inhibit ALDH1A1 activity. We therefore investigated whether ATRA could circumvent the resistance to improve the response to gefitinib in NSCLC/ADC cells. Treatment of NSCLC/ADC A549 and H1650 cells with gefitinib enriched the gefitinib surviving cells (GSCs). The expression of ALDH1A1 and CD44 and the IC50 values for gefitinib were determined by flow cytometry (FCM) and crystal violet assay in GSCs and ATRA-treated GSCs, respectively. Using DEAB as the positive control, direct inhibitory effect of ATRA on ALDH1A1 activity was determined by ALDEFLUOR assay, GSCs showed higher expression of ALDH1A1 and CD44 and IC50 values for gefitinib than their respective parental cells, suggesting that gefitinib can lead to propagation of CSC-enriched gefitinib-resistant cells. Treatment with ATRA was found to significantly reduce the increased expression of ALDH1A1 and CD44 and the IC50 values for gefitinib in A549GSC and H1650GSC cells, and ATRA could directly inhibit active ALDH1A1 as compared to DEAB. Our findings suggest that combination treatment with ATRA prevents gefitinib-induced enrichment of ALDH1A1bright/CD44high CSCs and enhances gefitinib-induced growth inhibition of NSCLC/ADC cells.
      datePublished:2020-04-15T00:00:00Z
      dateModified:2020-04-15T00:00:00Z
      pageStart:1
      pageEnd:9
      license:http://creativecommons.org/publicdomain/zero/1.0/
      sameAs:https://doi.org/10.1186/s12885-020-06818-0
      keywords:
         All-trans retinoic acid
         ALDH1A1
         CD44
         EGFR tyrosine kinase inhibitors
         Non-small cell lung adenocarcinoma
         Cancer Research
         Oncology
         Surgical Oncology
         Health Promotion and Disease Prevention
         Biomedicine
         general
         Medicine/Public Health
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12885-020-06818-0/MediaObjects/12885_2020_6818_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12885-020-06818-0/MediaObjects/12885_2020_6818_Fig2_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12885-020-06818-0/MediaObjects/12885_2020_6818_Fig3_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12885-020-06818-0/MediaObjects/12885_2020_6818_Fig4_HTML.png
      isPartOf:
         name:BMC Cancer
         issn:
            1471-2407
         volumeNumber:20
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Wenxiu Yao
            affiliation:
                  name:Medical School of University of Electronic Science and Technology of China
                  address:
                     name:Department of Medical oncology, Sichuan Cancer Hospital, Medical School of University of Electronic Science and Technology of China, Chengdu, People’s Republic of China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Liyang Wang
            affiliation:
                  name:Medical School of University of Electronic Science and Technology of China
                  address:
                     name:Department of Medical oncology, Sichuan Cancer Hospital, Medical School of University of Electronic Science and Technology of China, Chengdu, People’s Republic of China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Huan Huang
            affiliation:
                  name:Wuming Hospital Affiliated to Guangxi Medical University
                  address:
                     name:Department of Medical oncology, Wuming Hospital Affiliated to Guangxi Medical University, Nanning, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Xin Li
            affiliation:
                  name:Medical School of University of Electronic Science and Technology of China
                  address:
                     name:Department of Medical oncology, Sichuan Cancer Hospital, Medical School of University of Electronic Science and Technology of China, Chengdu, People’s Republic of China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Pinjia Wang
            affiliation:
                  name:Medical School of University of Electronic Science and Technology of China
                  address:
                     name:Department of Medical oncology, Sichuan Cancer Hospital, Medical School of University of Electronic Science and Technology of China, Chengdu, People’s Republic of China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Kun Mi
            affiliation:
                  name:Sichuan Cancer Insititute
                  address:
                     name:Department of Biochemistry & Molecular Biology, Sichuan Cancer Insititute, Chengdu, People’s Republic of China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jia Cheng
            affiliation:
                  name:Sichuan Cancer Insititute
                  address:
                     name:Department of Biochemistry & Molecular Biology, Sichuan Cancer Insititute, Chengdu, People’s Republic of China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Huifen Liu
            affiliation:
                  name:Sichuan Cancer Insititute
                  address:
                     name:Department of Biochemistry & Molecular Biology, Sichuan Cancer Insititute, Chengdu, People’s Republic of China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Cuirong Gu
            affiliation:
                  name:Sichuan Cancer Insititute
                  address:
                     name:Department of Biochemistry & Molecular Biology, Sichuan Cancer Insititute, Chengdu, People’s Republic of China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Lingxiao Huang
            affiliation:
                  name:Sichuan Cancer Insititute
                  address:
                     name:Department of Biochemistry & Molecular Biology, Sichuan Cancer Insititute, Chengdu, People’s Republic of China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jianming Huang
            affiliation:
                  name:Sichuan Cancer Insititute
                  address:
                     name:Department of Biochemistry & Molecular Biology, Sichuan Cancer Insititute, Chengdu, People’s Republic of China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:BMC Cancer
      issn:
         1471-2407
      volumeNumber:20
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Medical School of University of Electronic Science and Technology of China
      address:
         name:Department of Medical oncology, Sichuan Cancer Hospital, Medical School of University of Electronic Science and Technology of China, Chengdu, People’s Republic of China
         type:PostalAddress
      name:Medical School of University of Electronic Science and Technology of China
      address:
         name:Department of Medical oncology, Sichuan Cancer Hospital, Medical School of University of Electronic Science and Technology of China, Chengdu, People’s Republic of China
         type:PostalAddress
      name:Wuming Hospital Affiliated to Guangxi Medical University
      address:
         name:Department of Medical oncology, Wuming Hospital Affiliated to Guangxi Medical University, Nanning, China
         type:PostalAddress
      name:Medical School of University of Electronic Science and Technology of China
      address:
         name:Department of Medical oncology, Sichuan Cancer Hospital, Medical School of University of Electronic Science and Technology of China, Chengdu, People’s Republic of China
         type:PostalAddress
      name:Medical School of University of Electronic Science and Technology of China
      address:
         name:Department of Medical oncology, Sichuan Cancer Hospital, Medical School of University of Electronic Science and Technology of China, Chengdu, People’s Republic of China
         type:PostalAddress
      name:Sichuan Cancer Insititute
      address:
         name:Department of Biochemistry & Molecular Biology, Sichuan Cancer Insititute, Chengdu, People’s Republic of China
         type:PostalAddress
      name:Sichuan Cancer Insititute
      address:
         name:Department of Biochemistry & Molecular Biology, Sichuan Cancer Insititute, Chengdu, People’s Republic of China
         type:PostalAddress
      name:Sichuan Cancer Insititute
      address:
         name:Department of Biochemistry & Molecular Biology, Sichuan Cancer Insititute, Chengdu, People’s Republic of China
         type:PostalAddress
      name:Sichuan Cancer Insititute
      address:
         name:Department of Biochemistry & Molecular Biology, Sichuan Cancer Insititute, Chengdu, People’s Republic of China
         type:PostalAddress
      name:Sichuan Cancer Insititute
      address:
         name:Department of Biochemistry & Molecular Biology, Sichuan Cancer Insititute, Chengdu, People’s Republic of China
         type:PostalAddress
      name:Sichuan Cancer Insititute
      address:
         name:Department of Biochemistry & Molecular Biology, Sichuan Cancer Insititute, Chengdu, People’s Republic of China
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Wenxiu Yao
      affiliation:
            name:Medical School of University of Electronic Science and Technology of China
            address:
               name:Department of Medical oncology, Sichuan Cancer Hospital, Medical School of University of Electronic Science and Technology of China, Chengdu, People’s Republic of China
               type:PostalAddress
            type:Organization
      name:Liyang Wang
      affiliation:
            name:Medical School of University of Electronic Science and Technology of China
            address:
               name:Department of Medical oncology, Sichuan Cancer Hospital, Medical School of University of Electronic Science and Technology of China, Chengdu, People’s Republic of China
               type:PostalAddress
            type:Organization
      name:Huan Huang
      affiliation:
            name:Wuming Hospital Affiliated to Guangxi Medical University
            address:
               name:Department of Medical oncology, Wuming Hospital Affiliated to Guangxi Medical University, Nanning, China
               type:PostalAddress
            type:Organization
      name:Xin Li
      affiliation:
            name:Medical School of University of Electronic Science and Technology of China
            address:
               name:Department of Medical oncology, Sichuan Cancer Hospital, Medical School of University of Electronic Science and Technology of China, Chengdu, People’s Republic of China
               type:PostalAddress
            type:Organization
      name:Pinjia Wang
      affiliation:
            name:Medical School of University of Electronic Science and Technology of China
            address:
               name:Department of Medical oncology, Sichuan Cancer Hospital, Medical School of University of Electronic Science and Technology of China, Chengdu, People’s Republic of China
               type:PostalAddress
            type:Organization
      name:Kun Mi
      affiliation:
            name:Sichuan Cancer Insititute
            address:
               name:Department of Biochemistry & Molecular Biology, Sichuan Cancer Insititute, Chengdu, People’s Republic of China
               type:PostalAddress
            type:Organization
      name:Jia Cheng
      affiliation:
            name:Sichuan Cancer Insititute
            address:
               name:Department of Biochemistry & Molecular Biology, Sichuan Cancer Insititute, Chengdu, People’s Republic of China
               type:PostalAddress
            type:Organization
      name:Huifen Liu
      affiliation:
            name:Sichuan Cancer Insititute
            address:
               name:Department of Biochemistry & Molecular Biology, Sichuan Cancer Insititute, Chengdu, People’s Republic of China
               type:PostalAddress
            type:Organization
      name:Cuirong Gu
      affiliation:
            name:Sichuan Cancer Insititute
            address:
               name:Department of Biochemistry & Molecular Biology, Sichuan Cancer Insititute, Chengdu, People’s Republic of China
               type:PostalAddress
            type:Organization
      name:Lingxiao Huang
      affiliation:
            name:Sichuan Cancer Insititute
            address:
               name:Department of Biochemistry & Molecular Biology, Sichuan Cancer Insititute, Chengdu, People’s Republic of China
               type:PostalAddress
            type:Organization
      name:Jianming Huang
      affiliation:
            name:Sichuan Cancer Insititute
            address:
               name:Department of Biochemistry & Molecular Biology, Sichuan Cancer Insititute, Chengdu, People’s Republic of China
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Medical oncology, Sichuan Cancer Hospital, Medical School of University of Electronic Science and Technology of China, Chengdu, People’s Republic of China
      name:Department of Medical oncology, Sichuan Cancer Hospital, Medical School of University of Electronic Science and Technology of China, Chengdu, People’s Republic of China
      name:Department of Medical oncology, Wuming Hospital Affiliated to Guangxi Medical University, Nanning, China
      name:Department of Medical oncology, Sichuan Cancer Hospital, Medical School of University of Electronic Science and Technology of China, Chengdu, People’s Republic of China
      name:Department of Medical oncology, Sichuan Cancer Hospital, Medical School of University of Electronic Science and Technology of China, Chengdu, People’s Republic of China
      name:Department of Biochemistry & Molecular Biology, Sichuan Cancer Insititute, Chengdu, People’s Republic of China
      name:Department of Biochemistry & Molecular Biology, Sichuan Cancer Insititute, Chengdu, People’s Republic of China
      name:Department of Biochemistry & Molecular Biology, Sichuan Cancer Insititute, Chengdu, People’s Republic of China
      name:Department of Biochemistry & Molecular Biology, Sichuan Cancer Insititute, Chengdu, People’s Republic of China
      name:Department of Biochemistry & Molecular Biology, Sichuan Cancer Insititute, Chengdu, People’s Republic of China
      name:Department of Biochemistry & Molecular Biology, Sichuan Cancer Insititute, Chengdu, People’s Republic of China

External Links {šŸ”—}(197)

Analytics and Tracking {šŸ“Š}

  • Google Tag Manager

Libraries {šŸ“š}

  • Clipboard.js
  • Prism.js

CDN Services {šŸ“¦}

  • Crossref

4.57s.